Self-assembled pharmaceutical composition for photodynamic therapy
US-2016089436-A1 · Mar 31, 2016 · US
MRI contrasting agent for contrasting cancer cell
US9765187B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9765187-B2 |
| Application number | US-201514670805-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 27, 2015 |
| Priority date | Sep 26, 2014 |
| Publication date | Sep 19, 2017 |
| Grant date | Sep 19, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to MRI contrasting agent for contrasting cancer cell which contains ultrafine nanoparticles. More particularly, the present invention is directed to a self-assembled ligand composition comprising a ligand A, which is separated at a specific pH range, and a ligand B of which surface charge changes at a specific pH range, MRI contrast agent for contrasting cancer cell comprising said ligand composition and MRI contrasting nanoparticles, and the methods for preparing them.
First claim
Opening claim text (preview).
What is claimed is: 1. A ligand composition for use with a MRI contrasting agent comprising: a ligand A having the following structure: wherein n and m are independently an integer of 5-500, a ligand B having the following structure: wherein n and m are independently an integer of 5-500, wherein at a pH range of 4-7.2, the ligand A is separated from the MRI contrasting agent and the surface charge of ligand B changes from negative to positive.
Assignees
Inventors
Classifications
- C08G69/40Primary
Polyamides containing oxygen in the form of ether groups (C08G69/12, C08G69/32 take precedence) · CPC title
Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers (involving only carbon-to-carbon unsaturated bond reactions C08F299/00 {; polyester-amides C08G69/44; polyester-imides C08G73/16; polyamides-imides C08G73/14; block- or graft polymers containing polysiloxane sequences C08G77/42}) · CPC title
derived from amino-carboxylic acids · CPC title
the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9765187B2 cover?
- The present invention relates to MRI contrasting agent for contrasting cancer cell which contains ultrafine nanoparticles. More particularly, the present invention is directed to a self-assembled ligand composition comprising a ligand A, which is separated at a specific pH range, and a ligand B of which surface charge changes at a specific pH range, MRI contrast agent for contrasting cancer cel…
- Who is the assignee on this patent?
- Snu R&Db Foundation, Inst Basic Science, The Catholic Univ Of Korea Industry-Academic Coop Found, and 2 more
- What technology area does this patent fall under?
- Primary CPC classification C08G69/40. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Sep 19 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).